Podcasts about Arbor

In this special episode of The Golden Gang, host Chuck Nichols takes the podcast on the road to the annual Arbor Connections Conference in Atlanta, sitting down with colleagues from across The Arbor Company. You'll hear from engagement directors, memory care leaders, support partners, and company leadership, each with a unique story about what drew them to this work and what keeps them here. From Lee Jarrett's 17-year journey in Washington, D.C., to Gauri's fresh perspective after relocating from abroad, the voices in this episode capture what makes The Arbor Company a place people choose to stay. Listen in, and hear the passion behind the people.

Rogán megszűnő minisztériuma ezúttal elektronikusan adott ki közadatokat A politikailag lehetetlent teljesítették, a gazdasági csodára egy kicsit még várni kell Tizenhat év után már nem a felcsúti focicsapat alapítványa fogja üzemeltetni az Alcsúti Arborétumot Vizsgálat egy állami tankönyvellátó cég körül Tippelj, melyik intézményt hozza vissza a Tisza-kormány egészségügyi minisztere – felbukkant a tavaly kirúgott főigazgató is Lemond Trump hírszerzési vezetője, miután férjénél ritka csontrákot diagnosztizáltak Újra lezárta a kormány az ukrán agrárimport kapuit – itt a tiltólista! Lemondott posztjáról Bayer Zsolt felesége Új trükkel ürítik ki a magyarok bankszámláit: a legtöbben maguk utalják el minden pénzüket a csalóknak Nyugtalanítja a NATO-n belüli bizonytalanság a cseh államfőt Vett egy klubot, majd visszavonult a világbajnok Szoboszlai Dominik élete eddigi fénypontját hozta az elmúlt egy év – Azt is elárulta mi volt ez Akár a strandon is tölthetjük a pünkösdöt A további adásainkat keresd a podcast.hirstart.hu oldalunkon. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Rogán megszűnő minisztériuma ezúttal elektronikusan adott ki közadatokat A politikailag lehetetlent teljesítették, a gazdasági csodára egy kicsit még várni kell Tizenhat év után már nem a felcsúti focicsapat alapítványa fogja üzemeltetni az Alcsúti Arborétumot Vizsgálat egy állami tankönyvellátó cég körül Tippelj, melyik intézményt hozza vissza a Tisza-kormány egészségügyi minisztere – felbukkant a tavaly kirúgott főigazgató is Lemond Trump hírszerzési vezetője, miután férjénél ritka csontrákot diagnosztizáltak Újra lezárta a kormány az ukrán agrárimport kapuit – itt a tiltólista! Lemondott posztjáról Bayer Zsolt felesége Új trükkel ürítik ki a magyarok bankszámláit: a legtöbben maguk utalják el minden pénzüket a csalóknak Nyugtalanítja a NATO-n belüli bizonytalanság a cseh államfőt Vett egy klubot, majd visszavonult a világbajnok Szoboszlai Dominik élete eddigi fénypontját hozta az elmúlt egy év – Azt is elárulta mi volt ez Akár a strandon is tölthetjük a pünkösdöt A további adásainkat keresd a podcast.hirstart.hu oldalunkon. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Empezaremos visitando la cueva de hielo de Demänová – o Demänovská ľadová jaskyňa para abordar el problema de la desaparición, o mejor dicho del derretimiento del hielo en ella. Puesto que el mes de mayo es también el mes de florecimiento de numerosas plantas, seguiremos invitándoles a visitar el parque botánico de Arborétum situado en Tesárske Mlyňany. Terminaremos volviendo al tema de la cría tradicional de ovejas. Nos trasladaremos al este del país, más precisamente a la pintoresca región de Spiš para visitar la granja de Spišský salaš.

In this episode of The Golden Gang, engagement coordinator Angie sits down with Nicole, executive director of Arbor Terrace Middletown, for an honest conversation about what it takes to lead a senior living community. Nicole reflects on her path from the mortgage business into senior living, the childhood summers spent tagging along with her grandmother (a travel nurse) that first sparked her passion, and a family story that still sits on her mantel years later. Along the way, she shares her thoughts on compassion, trust, and why the bones of a community matter far more than a shiny new chandelier.

The Alan Cox ShowSee omnystudio.com/listener for privacy information.

The Alan Cox Show

John Maytham speaks to Mark Johnston, an exco member of Treekeepers Cape Town, about why it would be better to have a focus on tree planting in the Cape in late April, rather than during National Arbor Week in September. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Deb (00:03.606)Within the next seven months, up to 1.5 million Americans could lose access to a medication that they’ve relied on for decades. Not because it’s dangerous, but because a pharmaceutical giant may have lobbied the FDA to eliminate their competition. And if you’re one of them, your doctor may already have told you about this issue and stopped prescribing it.This isn’t a conspiracy theory. This is documented in federal court filings. This is happening right now. And the company that stands to profit, well, they’re the same ones manufacturing the only product that might survive.Today on Let’s Talk Wellness Now, we’re exposing the desiccated thyroid extract crisis, the corporate manipulation behind it, and what you need to do right now to protect your health. Stay with me because I’m about to share what could save your access to the medication keeping you alive.Welcome back to Let’s Talk Wellness Now, the show where we uncover the root causes of chronic illness, expose regulatory capture in healthcare, and empower you with the tools to advocate for yourself. I’m Dr. Deb, naturopathic doctor, your medical detective, and today we’re diving into one of the most consequential and corrupt healthcare decisions affecting patients right now. If you or someone you love takes Armour thyroid, NP thyroid, or any desiccated thyroid extract,for hypothyroidism or if you’ve struggled to find a thyroid medication that actually works for your body, this episode is absolutely critical. And if you have celiac disease, gluten sensitivity or corn allergies, what I’m about to reveal will make your blood boil. Now grab your cup of coffee, don’t forget your notebook and settle in because what’s happening to this medication right now is a masterclass in how pharmaceutical companies use regular Deb (02:06.544)agencies to eliminate competition, control markets, and price gouge patients. And I have all the receipts. Deb (02:20.982)Let me start with what might surprise you. Desiccated thyroid extract, or DTE as we call it, is actually one of the most oldest thyroid medications in the world. And I mean old. From the 1890s through 1970, this was the standard treatment for hypothyroidism.Now let’s really dive into that. From the 1890s to the 1970s, this was standard hypothyroidism treatment.In 1965 alone, and this is documented in peer-reviewed literature published in the Journal of Clinical Endocrinology and Metabolism, approximately four out of every five prescriptions for thyroid hormone in the United States were of natural desiccated thyroid preparations.The Journal of Clinical Endocrinology and Metabolism is a very high-end journal. Now think about that. This wasn’t some fringe therapy. This was mainstream medicine. Armour Thyroid, the most recognizable brand name, has been manufactured since the early 1900s, well over a century ago.and this is cited again in NIH bookshelf. When the FDA was officially established in 1938, Arbor thyroid was already on the market. And this is important and I want you to understand why. Under the federal Food, Drug and Cosmetic Act, any drug that was already being marketed before 1938 was automatically grandfathered into the system. That means it didn’t have to Deb (04:08.112)go through the formal FDA approval process. And this again is cited under the Federal Food, Drug and Cosmetic Act, grandfathered drugs and exemptions. And this is crucial to understanding what happens next. By the 1970s, synthetic levothyroxine, brand name Synthroid and generics became the preferred treatment. Hmm, wonder why?It was easier to standardize, came into consistent doses, and worked well for most patients, and could be mass manufactured. By the 1980s, levothyroxine had largely replaced desiccated thyroid in clinical practice, according to the American Thyroid Association 2014 guidelines for the treatment of hypothyroidism. But here’s what matters. Some patients…a very significant minority of them, never felt right on levothyroxine alone. Despite their lab work looking normal, they still had fatigue, brain fog, weight gain, cold intolerance, and depression.These patients often found relief when they switched back to their desiccated thyroid, which contains both T4 and T3 hormones, the way human thyroid naturally produces them. And this is not anecdotal. This is documented in randomized double-blind crossover studies published in Endocrine Practice.For decades, that was fine. Their doctors prescribed it, insurance sometimes covered it, patients were getting better, and the system worked really well. Until August 6th of 2025, just a short time ago, everything changed. On that date, the FDA sent letters to manufacturers, importers, and distributors of desiccated thyroid extract products stating that these medications would need an approval. Deb (06:04.654)a biologics licensed application, a BLA, to remain legally on the market. And this is cited in the FDA’s official statement, FDA’s actions to address unapproved thyroid medications. understand it says unapproved thyroid medications. However, desiccated thyroid, specifically Armour, has been approved since 1938. And this was dated August 6th through 7th, 2025.This wasn’t a guideline. This wasn’t a suggestion. It was an endorsement of action. And the timeline they gave them? Well, just 12 months to transition patients to another medication before enforcement action could begin.This was also cited by an FDA notice to the industry, animal derived thyroid products notice to industry, August 6th, 2025. Now do the math, that means August 2026, seven months from now, 1.5 million Americans currently taking this medication. And this number comes from the FDA official statement, citing that it’s an estimation of 1.5 million patients receiving prescriptions for these medications.could potentially lose their thyroid access. Now, here’s where it gets interesting. The FDA didn’t wake up in August of 2025 and decide to regulate desiccated thyroid after a century. This decision has a much longer backstory. And understanding that backstory is critical to understanding what’s really happening in this industry.The shift started in 2022. Back in September of 2022, over three years ago, an FDA branch chief sent a letter to the National Associations of Boards of Pharmacy noting that the agency had decided to designate DTE as a biological product, which would affect its eligibility for compounding. Deb (08:13.972)This also is cited in an FDA letter to the National Association of Boards of Pharmacy September 2022.Then two months later, in November of 2022, the FDA’s Office of Compounding Quality and Compliance sent a softer letter acknowledging that many Americans take medication to treat hypothyroidism and some choose to take DTE products. The letter stated that the FDA would focus enforcement on cases that pose the greatest public health risks, such as serious adverse offense or serious product quality or adulteration.also is cited by an FDA letter from Francis G. Bromel, the director, Office of Compounding Quality and Compliance, November of 2022. Now, let me just think about this for a second. If this drug has been on the market since the 1800s, been FDA approved since 1938, would we not have seen a health crisis long before 2022?I honestly don’t know of any other drug that’s been around this long that’s used by this many people. Now granted, I haven’t done the research on it either, which I can do for you guys, but I’m just thinking if a drug is on the market today and it causes harm, it doesn’t make it three years, five years before you see lawsuits everywhere. Why are there no lawsuits on this drug? Why are there no major reactions that people are seen having?Hmm, just thought. But here’s the pattern. The FDA was already laying the groundwork back in 2022, testing the waters, signaling where this was headed. The August 2025 action. Then this came down. Deb (10:09.806)August 6, 2025, the FDA announced its position publicly and sent formal letters to all DTE manufacturers, importers, and distributors. This was cited by the FDA Enforcement Action August 6, 2025, letters to manufacturers, importers, distributions of DTE products. The agency stated several concerns. First, DTE products have experienced quality and dosing issues.The FDA cited, and I’m quoting directly from their statement, over 500 adverse events reported associated with DTE products from 1968 to 2025. From 1968 to 2025, we had 500 adverse reactions? What is that math equate to?A couple a year? Come on guys, this is insane! With a substantial increase, you, between 2019 and 2020 that the agency suggested was related to voluntary recalls of sub-potent or super-potent products.This was cited in the FDA statement, over 500 adverse events reported associated with ADT products from 1968 through 2025.Second, the agency expressed concern about batch inconsistency. According to the FDA’s official statements, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Okay, this was cited in the FDA statement, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Thirdly, and I want to actually let’s back up. I want you to remember I said that Deb (12:11.216)because further down in this podcast, we’re going to talk about this. This is an important point to remember. Thirdly, the agency raised concerns about potential impurities from animal source material, including potential for viral contamination due to the animal source and supraphysiological levels of T3.the FDA statement on impurities, viral contamination and super physiological T3 levels. Now I will tell you, I’ve been prescribing armarithograde for 20 years. I’ve rarely seen a super physiological dose given of T3 in lab results, unless the patient takes their medication like four or five hours before you do the blood test, then you’ll see a false rise because you’re actually seeing the medication. You’re not seeing people walking aroundsuperphysiological T3 levels. Nobody would like that feeling. So anyway, I digress. Now let me pause here because this is where I need to give you some context that the FDA hasn’t quite emphasized yet. Of course, we have another connection and it is the China connection.So the FDA’s concerns about contaminated drugs and quality issues don’t exist in a vacuum. In 2024, the U.S. over 828,000 metric tons of pharmaceuticals, seven times the level from 2000. And here’s the kicker. China and India supply the majority of active pharmaceutical ingredients. APIs for U.S. generics accounting for 70 to 80 % of the total genericdrug supply. According to Reuters industry report in 2024, they state that China supplies 82 % of the APIs for critical drugs. Deb (14:08.204)Got to question that, right? Why are we giving all of our drug formulas to China and allowing them to import them into our country? In fact, roughly 20 % of the critical drugs have APIs exclusively sourced from China. And China controls 80 to 90 % of the global production for antibiotics and other key compounds. This was also cited by Reuters industry data thatcontrols 80 to 90 percent of the global production for antibiotics and other key compounds. Now just think about this. They control 80 to 90 percent of our medication. They control 20 percent of our critical drugs and we just put what kind of tariff on them? Hmm.In 2025 alone, the FDA issued multiple warning letters to foreign manufacturers for contamination issues and failure to follow good manufacturing practices. This is also cited by the FDA warning letters 2024 through 2025 and multiple citations to foreign manufacturing facilities. This is a systematic problem affecting the entire US drug supply, not just desiccated thyroid.So when the FDA suddenly became concerned about DTE quality and contamination, part of that concern was legitimate. But this is crucial. The same inconsistencies and contamination issues exist across the entire generic drug supply. And the FDA has not taken the same enforcement action against them. Let that sink in.They have not taken the same enforcement action against the other drug companies. So what’s behind all of this? Where is this all coming from? Hmm. Let’s address something directly, because you deserve to know it. And I’m going to cite my sources precisely so that when the medical boards have something to say about this, and they might, I have a documentation for every single word that I am about to speak. Deb (16:24.878)According to the court documents filed in October 2025, in the case ofa urine, a urine. I’m going to say that wrong. Pharmaceuticals versus Dr. George Tidmarsh from ABBV, the multinational pharmaceutical company that manufactures armor thyroid, reportedly petitioned the FDA in 2024, asking the agency to reclassify DTE as a biologic and to prohibit other manufacturers from selling unlicensed DTE products unless they havehad an investigational new drug application, we call this an IND, and a clinical development program aimed at eventual approval. This is cited in the court filing a Urena pharmaceuticals lawsuit versus Dr. George Tidmarsh, October 2025, reported by Fierce Pharma. Now let me explain why this matters and why this is one of the most brazen examples of regulatory capture I’ve ever seen in my career.AbbeVee is one of the world’s largest pharmaceutical companies. In 2024, they reported over $54 billion in revenue. Drop the mic on that one.They have the resources, the regulatory expertise, the legal teams, and the financial capacity to navigate a biologics license application process that costs between $500 million and $1 billion. Let that sink in. Deb (18:07.882)A drug that’s been on the market since the 1800s that was grandfathered in 1938 that’s making plenty of money right now. They’re going to spend 500 million to $1 billion to get a biologics license application. Why would they do that? Well, we’re about to find out. Most otherDTE manufacturers, smaller companies like Acela Pharmaceuticals, which makes NP-thyroid, and RLC Labs, which made WP-thyroid, do not have those same resources. And this is cited in Pharma Voice in 2025. Why a treatment older than the FDA is getting new regulatory scrutiny. So when you petition the FDA to reclassify a drug in a way that requires this type of expensivetime-consuming biological approval, you’re not just asking for safety. You’re asking to eliminate your competitors from the marketplace. Now, I want to be very precise here. These allegations are documented in federal court filings, and it hasn’t been approved in court. It’s also been reported by multiple industry sources, including Fierce Pharma. But I’m telling you,what has been reported in legal proceedings, not stating it as an absolute fact because you deserve to know the difference and because I have to protect my license. Now, what do we know for certain?AbbeVee is working on a biologics license application for Armour thyroid through clinical trials called Avantia. This is cited by the AbbeVee corporate statement 2025 Avantia clinical trial for Armour thyroid. A cell of pharmaceuticals has been pursuing BLA approval for NP thyroid for seven years since 2017 and it completed its phase two trials successfully in 2025. They’re now moving Deb (20:15.448)into Phase 3 trials. This is also cited by the Acela Pharmaceuticals CEO statement 2025 seven-year pursuit for BLA approval completed Phase 2 trials moving to Phase 3.RLC Labs, which manufactured WP thyroid, has made no public announcement about pursuing BLA approval and really probably don’t have a plan to do this since they’ve been off the market for some time now. About five years, I think maybe a little longer. Here’s the market manipulation.If only ABBV is successful and obtains a BLA approval for Armour thyroid, that company would effectively have a monopoly on the DDT market. And in pharmaceutical markets, monopolies historically lead to price increases.We’ve seen this pattern over and over again when turning pharmaceuticals acquired Daraprim and raised their price from $13.50 to $750 per tablet overnight. When Myelin raised EpiPen increased prices by 400 % when insulin manufacturers colluded to raise prices in lockstep. This is the playbook.use regulatory barriers to eliminate your competition and then exploit pricing power. For a drug that’s been on the market since the 1800s, guess corporate greed is everywhere. They’re not making enough money on this product already and they’re taking advantage of the rules that they can manipulate their competition by. And here’s what really makes me furious. The American Thyroid Association, the professional organization Deb (22:06.672)representing endocrinologists sent letters to the FDA commissioner on October 8th of 2025 and September 18th of 2025.advocating for continued patient access to DTEs. This is cited in the American Thyroid Association statement and letter to the FDA commissioner dated October 8th, 2025 and September 18th, 2025. The American Association of Clinical Endocrinologists issued a statement on September 9th of 2025 supporting equitable access and personalized medicine for DTE. This was also cited in the American AssociationAssociation of Clinical Endocrinologists, AACE, statement dated September 9th, 2025. Even the medical establishment, which has historically favored levothyroxine, is saying, wait, this is going too far. Patients need access to this medication. But the FDA is moving forward anyway. Why? Well, where does it always lead us? Follow the money trail.Okay, so I need to explain what a biologics license application actually is because this is where the rubber meets the road for what’s going to happen to pricing and availability. What is a BLA?A BLA is a biologics license application. It’s a formal request submitted to the FDA to market a biologic product in the United States. A biologic is defined under the Public Health Service Act section 351 as a product derived from or made using living material, in this case, animal thyroid glands. And this is cited in the FDA definition for biologic products. So they’re putting armor thyroid right Deb (23:57.377)right up with stem cells and exosomes. Think about that. Stem cells and exosomes cost thousands of dollars per application because of how they have to be harvested, stored, freezed, all of that. But we’re talking about a thyroid gland. Good Lord, people.Unlike regular drug applications for synthetic medications which follow a simpler pathway, the BLA process is designed for complex biological products like monoclonal antibodies, vaccines, and gene therapy products. It’s a much more expensive, much more time-consuming process. The BLA processis what manufacturers have to do. And we’re going to talk about that. So according to Reprocell and Forge Biologics analysis of the FDA’s BLA process, here’s what companies need to submit. First, they need to complete a clinical trial data, phase one, two, and three trials, proving safety and efficacy for desiccated thyroid. Haven’t we done that since it’s been on the market since the 1800s? Just saying.This means they have to conduct large randomized controlled trials comparing it to levothyroxine, measuring safety outcomes, efficacy outcomes, and quality of life metrics. Second,Chemistry, Manufacturing and Controls, CMC’s data. Detailed information about how the product is manufactured, quality control measures, stability testing and specifications that must be met for every batch. Third, preclinical and animal safety data. Fourth, labeling and product information. Now, I think we have labeling and product information. Deb (25:53.717)since the 1800s? But just saying. Fifth, they need Pharma Covigilance Plan, a detailed plan for monitoring safety after the product is on the market. Haven’t they had to do that since the 1800s? And they have to have a timeline. And this is the critical part. The FDA’s standard review time for a BLA is 10 months.That’s after the application is deemed complete and accepted for filing. So this is cited by the FDA standard review timeline, BLA submission, and FDA review.Now, before you even get to filing, you need to conduct the clinical trials and compile all the data that’s typically several years of work. How are you going to prove safety and effectiveness in a large clinical trial long term? What do they consider? What do they deem long term? Three months, six months, a year, two years. These companies had 10 months.Well, maybe 12. They did it a year in advance. But unless you knew this was coming, how are you going to put together a trial, enroll the people, have all the trial components set up and ready to go in less than 12 months unless you knew it was coming beforehand? Even ifhad started all their clinical trials in 2024, completing them, compiling the data, and getting a complete application ready for submission, this would likely take you through mid-2026, then add another 10 months for FDA review. We’re looking at 2027 at the earliest for most of these companies to receive a BLA application. Deb (27:54.319)But the FDA gave the manufacturers until August of 2026. That’s approximately 19 months from when the August 2025 letters were sent. Most companies cannot reasonably complete the BLA approval in that timeframe. And when I’m talking about the 19 months, I’m talking about the information they would have had earlier. Now the cost.This gets me even more frustrated. Why are we spending this kind of money? The BLL process is extraordinarily expensive. The current FDA user fee for a BLA submission is approximately $483,560 just for the filing fee. And this is cited at the FDA user fees prescription drug user fee rates for 2025.The full cost of conducting clinical trials, CMC studies, and all the supporting documentation typically ranges from $500 million to over $1 billion, depending on the scope of the trials and the complexity. And this is cited in JAMA’s network, Open2023. A cell of pharmaceuticals has been pursuing the BLA approval since 2017. That’s eight years. And it’s just now.moving into phase three trials with a planned enrollment of approximately 300 patients. This is cited by the Acela Pharmacies CEO statement of 2025. Now that’s unusual. That’s typical for this process. This is not unusual. This is typical for this process to take seven, 10 years to get approval for this. So if Abby’s the one that requested this,Abby V. And Acela started this in 2017. Was Abby V threatened by Acela that Acela might get this approval and it would be quietly done without anybody seeing it? And maybe Abby V would be left out of the market after a century? Who knows? It’s possible. Deb (30:13.112)But for smaller manufacturers without billions in revenue, this cost is completely prohibitive. And this is why this matters. When you push an old established medication through an extraordinary, expensive approval process with a compromised timeline, one of three things happen. First, only the largest companies can afford it, creating a monopoly. And when that happens, the company that holds the only approved product can set pricing withminimal competitive pressures. Two, smaller manufacturers can’t afford it and their products disappear and the market shrinks and access decreases. Three, we see a combination of both and who pays the price? Literally, patients do. Now here’s whereThere’s something I want you to really think about because this is where the regulatory argument falls apart when you look at it carefully. The FDA’s concern about DTE is that, and I’m quoting their official statement, tablets from the same manufacturing batches may not always provide the same thyroid hormone levels. This is from their FDA statement.And that’s a legitimate quality concern, right? It is. Thyroid medications have a narrow therapeutic window like any other hormone, meaning the difference between an effective dose and the dose that causes problems can be quite small. But here’s what the FDA doesn’t emphasize. Generic drugs have the exact same dosing inconsistency issue, and it’s considered acceptable and has been since we allowed generics on the market.So how does a generic drug dose work anyway? Well, for generic drugs to be approved as bioequivalent to a brand name medication, the FDA requires that the generic drugs bioavailability fall within 80 to 125 % of the brand name product. Isn’t that a dose inconsistency? Deb (32:22.894)from the brand name medication? 800 or sorry, 80 to 125%. According to the pharmacy times analysis of the FDA’s bioequivalent standards, the 80 to 125 % bioequivalence rule means that a generic drug can have 20 to 45 % variability compared to the original brand product.Now, most generics are much closer than that. The FDA study data shows that the mean difference for an AUC value between generic and reference products is about three and a half percent in the two year post-Waxman hatch period, and 80 % of the generics fall within a five percent range. But the FDA’s regulations allow for that much higher variability. And this is cited in an FDA study data mean difference for AUC.Now, let me put this in plain language. A patient could take a generic levothyroxine tablet where one batch provides, say, 75 micrograms of an active thyroid hormone. And the next batch from a different manufacturer, a different generic manufacturer, could provide up to 93.75 micrograms, 125 % of that 75. That’s an 18 microgram difference.in the same prescribed dose. Now, this is considered acceptable and patients tolerate it and this system works.Yet the FDA’s argument against DTE is that batch-to-batch inconsistency is unacceptable and requires this expensive biologic approval? That’s a double standard. So why is batch inconsistency acceptable for generic levothyroxine, but supposedly unacceptable for desiccated thyroid? I’ll give you the regulatory answer. Deb (34:29.366)because DDT is a biological product derived from an animal tissue and the FDA considers biological products to require more rigorous control. That’s the regulatory answer, but I’ll give you the real answer.because there’s no billion dollar pharmaceutical company with a patent pending on generic levothyroxine who petitioned the FDA to regulate their competitors more strictly. The inconsistency argument is legitimate, but it’s selectively applied. And that matters when you’re trying to understand whether this is really about patient safety or whether it’s about market control.Now I want to talk about something that hasn’t gotten nearly enough attention in this discussion and it’s something that makes me absolutely furious. What is Armour Thyroid? According to the official prescribing information published by AbbeV and available through rxabbev.com and the FDA’s daily med database, Armour Thyroid contains the following inactive ingredients. Calcium steroid,dextrose derived from corn, mycocrystalline cellulose,sodium starch glycolate and a opadri white coating. Now let’s talk about dextrose. Dextrose is a sugar derived from corn and while manufacturers claim that the corn derived dextrose in armor thyroid is gluten free, here’s the problem. Cross contamination during corn processing can introduce gluten proteins especially if the corn is processed in facilities that also handle Deb (36:18.808)wheat, barley, or rye. Corn sensitivity is extremely common in patients with celiac disease and non-celiac gluten sensitivity, and studies show that up to 50 % of the celiac patients react to corn proteins due to molecular mimicry, and the corn proteins look similar enough to gluten that the immune system attacks them. And this is cited by RestartMD.com.And here’s what’s documented in peer-reviewed medical literature in a 2023 case report published in Case Reports in Endocrinology. These researchers documented five patients with gluten intolerance or celiac who were taking natural desiccated thyroid. Three of those patients also reported lactose intolerance. Now these patients had to switch from DTE to liquid levothyroxine formulations to avoid the inactiveSo here’s my question. If AbbeV becomes the only manufacturer with an approved DTE product and their formulations contain corn-derived dextrose that triggers reactions in celiac patients, what are those patients supposed to do? They can’t take armor because of the corn. They can’t take compounded DTE because the FDA is banning compounding of these biologics. They can’t take NPKsor WP thyroid because those companies may not survive the BLA process. So they’re left with a synthetic version of levothyroxine which may not work for them.Now the NP thyroid and WP thyroid difference. Now here’s what’s interesting according to drugs.com comparison of inactive ingredients and P thyroid and P thyroid has calcium steroid dextrose also derived from corn, mineral oil, multi-crystalline cellulose. Deb (38:19.31)cross carmelicin sodium and a opadri to white. So NP thyroid also has corn-derived dextrose. WP thyroid on the other hand was specifically formulated to be hypoallergenic according to ROC labs, but it’s no longer available and its ingredients were inulin from chicory root and medium chain triglycerides. No corn, no gluten, no common allergies. So todayWe do not have a glandular thyroid, a DTE, that is not potentially contaminated with gluten. Yet, patients with autoimmune thyroid disease are supposed to avoid gluten.Now, some of these people can handle a DTE and many cannot, so that argument could be a mute point. But at the end of the day, the one product that we had that was designated for patients with multiple chemical sensitivities, celiac disease and coron allergies, has been off the market for a long time already.We have a monopoly problem. So if ABBV becomes the only approved manufacturer, patients with these celiac diseases and corn allergies will either be forced to take a medicine that makes them sick and triggers their immune reaction or switch to a synthetic that doesn’t adequately treat their hypothyroidism or choose to go without treatment. This is not hypothetical. This is real patients with real medical needs who are about to lose accessto the only formulation that works for their body. And the FDA’s response is silence. Deb (40:07.69)Now I want to highlight something that hasn’t gotten nearly enough attention in this discussion. Compounding pharmacies. What is a compounding pharmacy? Compounded medications are custom made by licensed pharmacists to meet a patient’s specific needs. Maybe you need a different strength that was commercially available, but you have an allergy to a filler or a dye in the commercial product. Maybe you need a liquid formulation or instead of a tablet or you need a capsule. That’s when compoundingin. And the FDA’s, this is the FDA’s definition of compounding. And for decades, compounding pharmacies have been making desiccated thyroid extract for patients who needed customization. Some patients couldn’t take the commercial products because of the dyes and the fillers, and some needed strengths that were not available. And these compounding pharmacies filled the gap.But reclassification changes everything. When the FDA reclassified DTE as a biologic in 2022 and reinforced that decision in August of 2025, explicitly stated, and I’m quoting directly from the FDA’s official statement, these unapproved animal-derived thyroid medications are not eligible for compounding because these products are regulated as biologic products under the Public Health Service Act.How can that be? These products have been approved since 1938 and the Biologics Act didn’t go into effect or doesn’t go into effect until August of 2026.So how in 2022 were they able to say that the compounding pharmacies could not make these products? Anyway, what this means is after August 2026, compounding pharmacies will no longer be permitted to compound a desiccated thyroid extract, even for patients with specific medical needs. Now, compounding pharmacies can still compound T4 and T3 separately, synthetic versions of levothyroxine and liothyronine, according to Deb (42:12.728)healing dose compounding pharmacy. These pharmacists can create custom ratios of these two synthetic hormones to approximate what a patient was receiving from a DTE. But that’s not the same thing. Some patients respond better to the whole DTE preparation than to a compounded synthetic combination. And for patients with specific allergies to standard fillers like your celiac patients that I just talked about, losing the ability to get a compounded DTE alternative isreal hardship. This is going to be a ripple effect. For a subset of patients, maybe 5 to 10 percent of those on DTE compounding was their lifeline and it was their way to get a medication formulation that worked for their unique body. When compounding goes away, these patients lose that option as well and for some it will be a significant problem. Now let’s talk about what this likely means for your wallet.The current pricing right now, according to SingleCare and GoodRx, Armour Thyroid costs approximately $150 to $157 for a 90-day supply of 60-milligram tablets, about $1.67 per tablet. With discount cards, some patients can get it down to $101 to $152 for a 90-day supply.Generic levon thyroxine costs about $70 for a 90 day supply, less than half that price. And p-thyroid costs approximately $133 for a 90 day supply of 60 milligrams with a discount card about $83 to $101.What happens after we get BLA approval? Well, here’s the pharmaceuticals pricing model. When a company spends 500 million to $1 billion to bring a product to market, including conducting massive clinical trials, the cost tens of millions of dollars they recoup in that investment through pricing power. And this is cited in the pharmaceutical pricing models. If ABBIEV is the only company with an approved BLA of DTE, Deb (44:18.248)They have pricing power. They don’t have competitors. They can set their price, whatever they want. And historically, when drugs transition from grandfather status, which is basically unregulated to formal formally approved status, prices often increase significantly, not always, but often. And typically they have to get re-approval for insurance. SoTouring Pharmaceuticals acquired DARPM and raised the price again from $1,350 to $750 overnight, a 5,000 % increase. This is the playbook.Let’s talk about insurance coverage. This is the other consideration. Insurance companies sometimes have different coverage policies for approved versions versus unapproved drugs. And right now, many insurance plans cover armor thyroid or NP thyroid, even though they’re technically unapproved because they’ve been on the market for decades and patients are on them. Once a drug becomes formally approved, insurance companies may have new contractual relationships, prior authorization requirements, or preferred drugs.list that could affect your coverage. If 1.5 million people have to get a prior auth for their insurance to cover this new medication, this is going to drive the doctor’s offices crazy. We do not have the staff to man this. We do not have the manpower. We do not have the time. This is going to interrupt people’s ability to get their medications. This is going to create chaos within the system. And some patients might see better coverage, but manymost likely are going to see worse coverage and some might find themselves in a situation where they need to try to get the drug approved first or get an approval for something else like levothyroxine and they’re going to have to document that it didn’t work and the documentation that they had from 20 years ago is probably not going to be enough because it’s not documented anywhere. It’s lost in the system after 10 years. So for patients the practical takeaway is expect Deb (46:25.774)a price increase. I would say possible, but I don’t think that’s true. think you’re going to see a price increase if they get approved. Expect possible insurance complexities, budget accordingly, talk to your insurance company now about what your coverage is going to look like in 2027 if they even know. And if you want my honest assessment of what is likely to happen,I’ll give you a scenario, 30 % likelihood. The FDA enforces the August 26 deadline and DTE products not approved by then are pulled from the market. Patients will have 30 to 90 days to transition to other medications. Some patients suffer significant symptom relapse. Compounding for DTE becomes illegal and this disruptiveness of the system creates a real hardship. Scenario two.which is 50 % likely. This is actually what the FDA commissioner, Marty McCreary suggested on August 13th of 2025 when he posted on social media. The FDA is committed to pursuing the first ever approval of desiccated thyroid access pending results of the ongoing clinical trials. In the meantime, we’ll ensure access for all Americans. Hopefully that continues. What this likely means is the FDA uses enforcement discretion to allow continuedsales while approvals are being pursued and the deadline gets extended. Maybe patients get access for another two to three years while companies work on a BLA approval. This would be the least disruptive scenario, but it’s also legally uncertain because the enforcement letters have been formally rescinded. And scenario three, which is 20 % likelihood, one or two companies get BLA approval. Those products stay on the market at higher product prices and companies, products, other companiescompanies, products are pulled, the market shrinks, availability is limited, prices are higher, but patients can still get something. This is likely if a seller successfully completes phase three trials for NP-thyroid. And my assessment is based on the regulatory language and the enforcement letters that have not been rescinded yet, that the pattern of FDA enforcement, I believe scenario two enforcement discretion with an extended time frame is most likely what we’re going to see. Deb (48:49.488)doesn’t mean patients should sit back and do nothing. It means you should be prepared for change while advocating for access. If you want to keep Arm or Thigh Right on the market, 1.5 million people need to start talking about this publicly and flooding our Congress people, Bobby Kennedy, the FDA, with what you want to see happen. We have the ability to shape this and to change this with our voice. But if we sit back on our laurels and we do absolutelynothing. What is going to happen is what the FDA wants to have happen and ABV wants to have happen because they’re going to simply think people don’t give a shit. And if the American people are going to be lazy and not want to step forward and actually start using their voice for some good and instead of just going to social media and bitching and hoping something is going to happen, well, then we’re going to get what we deserve. But if you start taking someaction and you start advocating for the things that you want. Contacting your representatives, contacting your U.S. tell them the FDA has done this. Many of them may not know this, may not be on their radar. Tell them what you want. Start going after this. Start writing to the FDA Commissioner’s Office. They have a website. They have a Commissioner’s Office at fda.hhs.gov. Be responsible.respectful, but be firm. Explain your scenario. How long you’ve been on DTE. Why levothyroxine doesn’t work. What symptoms you experience when not adequately treated. How this decision will affect your quality of life and your pocketbook. Let’s do something proactive. So let’s consider this. Moving forward, work with your provider who understands the regulatory landscape around DTE. You can discuss the evidence for and against combination therapy.You can monitor for thyroid function with free T3 and free T4 testing, not just TSH. If you’re willing to try individualized approaches, you can do that. If you need help finding a functional medicine provider who understands this issue, come to serenityhealthcarecenter.com or explorethevanari.com. It’s a self-directed functional medicine support group. And right now what is happening is going to shape how history Deb (51:19.024)is made with not just armor thyroid, but many drugs to come. And it is important for you to take action. So I want to thank you for joining me today on Let’s Talk Wellness Now. This episode is about far more than thyroid medication. It’s about your right to personalized medical treatment. It’s about your regulatory capture and corporate influence. And it’s about what happens when billion dollar companies shape healthcare policy in ways that reduce patient choice and increase their profits.this episode resonates with you or you know somebody who’s going to be affected by desiccated thyroid, please share it. Post it on social media, send it to your doctor, email it to your representatives, tag AbbeVee, tag FDA. Make noise because the only way we stop this is if we make it too politically costly for them to continue. Your voice truly matters. Your health truly matters and you deserve access to treatments that work best for your unique body.If you’re ready to explore comprehensive personalized health care that puts you in control, visit us at SerenityHealthCareCenter.com. Learn more about functional medicine approaches to thyroid and beyond and explore my new platform, Venari.com, which is a self-directed functional medicine tool. Thank you for joining me today. Until next time, I’m Dr. Deb reminding you, your health is your responsibility, your choice, and your right. Be well, stay informed, fight back.and I’ll see you in the next episode. And if you’re looking for a full citation list of this episode, you can head over to letstalkwellnessnow.com and I will post all the citations for you so you have them in your arsenal as well. Thank you again.The post Episode 259 – The Desiccated Thyroid Crisis: FDA's Unseen Impact & Corporate Manipulation first appeared on Let's Talk Wellness Now.

Send me a messageAI may be booming, but the real bottleneck to it's growth may be turbines. And if firm power can't scale fast enough, parts of the energy transition hit a wall.In this episode, I'm joined by Brad Hartwig, Co-founder and CEO of Arbor Energy, to unpack a part of the climate tech and energy transition story that gets far too little attention: the physical machinery needed to deliver reliable, round-the-clock power. Arbor is developing modular supercritical CO2 turbines with integrated carbon capture, aimed at tackling one of the hardest problems in decarbonisation: how to provide firm, scalable electricity while still driving emissions reduction and keeping net zero in view.We dig into why turbine shortages are becoming a serious constraint on hyperscale data centres, utilities, and industrial electrification, and you'll hear why Brad believes this is now a critical choke point for both AI infrastructure and climate progress. You might be surprised to learn how stretched the traditional turbine supply chain has become, and why legacy manufacturers may be structurally mismatched to meet the moment.We also get into oxy-combustion, methane leakage, biomass, carbon sequestration, long-duration storage, and the awkward reality that wind, solar, batteries, and grid expansion, while essential, may still leave gaps when it comes to firm power. This is a grounded conversation about climate tech, policy, energy transition strategy, and what serious infrastructure thinking looks like when the easy slogans run out.

Voyager Ventures backs early-stage climate companies at seed and Series A with ~$475M AUM. Leo Banchik shares how they evaluate opportunities across unit economics, technology risk, and founder-market fit in a capital-constrained environment.In this episode:Unit economics > climate narrative - Companies like Arbor stand out because they work without subsidies. That's becoming table stakes.Clean-sheet innovation still wins, but only selectively - Conifer's motor redesign shows VCs will back first-principles tech, but only when the performance delta is clear and defensible.Battery assumptions are being reset - Investors are revisiting prior “no-go” categories as chemistries and cost curves shift.“No” is often provisional  - Voyager tracked companies like Electroflow over time. Relationship building can convert early rejection into later investment.AI is now embedded, not differentiated  - Tools like Allie AI show that automation is expected. It's not a moat unless tied to proprietary data or workflow lock-in.Founder profile: conviction + adaptability  - Best teams combine strong technical beliefs with a willingness to update assumptions quickly.Key decision for foundersBuild a climate company that needs subsidies to survive… or one that works on pure economics?--Work with me (EFI)Private CEO group (capped at 50) for climate tech founders navigating capital, strategy, and scale → entrepreneursforimpact.comNewsletter (Climate CEOs)3 decisions per week on climate finance, strategy, leadership → entrepreneursforimpact.substack.comLeave a reviewIf you got value, take 30 seconds and do the community a favor. It helps push more capital and talent toward scalable climate solutions.

Poplar trees are perhaps one of the lesser-known trees that I've featured on this blog. Many people can recognise an oak tree on sight, but how many could recognise the poplar?  Indeed, how many would realise John Constable added a black poplar to the background of his famous painting, 'The Hay Wain'? We find these trees in the willow family, and for a tree that's less common now, they have a surprising amount of folklore. The trees even gave their name to the London borough, Poplar, due to the number of black poplars in the area.  There are also different types of poplar, though this article will focus on the black and white varieties. So how did people use the tree in their remedies, and what superstitions surround the poplar? Let's find out in this week's episode of Fabulous Folklore! Find the blog post with all the images and references here: https://www.icysedgwick.com/poplar-trees/ Check out the Woodland Trust: https://www.woodlandtrust.org.uk/ Donate to Secure The Rothbury Estate: https://www.wildlifetrusts.org/appeals/rothbury-estate-nature-and-nation Get your free guide to home protection the folklore way here: https://www.icysedgwick.com/fab-folklore/ Become a member of the Fabulous Folklore Family for bonus episodes and articles at https://patreon.com/bePatron?u=2380595 Get weekly articles and bonus content at Substack: https://fabulousfolklore.substack.com/ Buy Icy a coffee or sign up for bonus episodes at: https://ko-fi.com/icysedgwick Fabulous Folklore Bookshop: https://uk.bookshop.org/shop/fabulous_folklore Pre-recorded illustrated talks: https://ko-fi.com/icysedgwick/shop Request an episode: https://forms.gle/gqG7xQNLfbMg1mDv7 Get extra snippets of folklore on Instagram at https://instagram.com/icysedgwick Find Icy on BlueSky: https://bsky.app/profile/icysedgwick.bsky.social 'Like' Fabulous Folklore on Facebook: https://www.facebook.com/fabulousfolklore/

Singer-Songwriter Arbor Mae talks beginnings as a musician, inspirations, and upcoming showcase at Mojos Cafe on March 27th

This week on Bumming with Bobcat, things get classy… well, as classy as they can get around here.Bum Wine Bob and Roadhouse welcome special guest Amy Reiley, to talk about the world of aphrodisiac foods, romantic flavors, and the science (and myths) behind foods that are said to spark the mood.But since this is Bumming with Bobcat, we're also diving headfirst into the legendary world of Arbor Mist — the fruity, budget-friendly wine that's been a staple of questionable decisions and late-night convenience store runs for years.Amy also gives us her favorite budget wines at the moment that will get the job done without breaking the bank!Check out Amy's work here: https://www.eatsomethingsexy.comCan fine dining and bum wine coexist? We're about to find out.Grab a drink and join us for another wild episode of Bumming with Bobcat!

Dnes budeme skloňovať slová ako regeneratívne poľnohospodárstvo, agrolesníctvo, či živá pôda. Pricestuje za nami vedec, ktorý nám predstaví jedinečný priestor, kde sa v reálnych podmienkach testujú, porovnávajú a demonštrujú nové prístupy k hospodáreniu s pôdou a krajinou. To miesto by ste našli v známom Arboréte Mlyňany. Na polhektárovom pozemku rastú v radoch agáty, levandule a byliny a medzi nimi poľnohospodárske plodiny. A to všetko bez pesticídov, organického či anorganického hnojivá. O návrate od priemyselného poľnohospodárstva k prírodnému hospodáreniu bude reč dnes popoludní s Petrom Ferusom, z Oddelenia dendrobiológie Ústavu ekológie lesa SAV. | Hosť RRZ: Peter Ferus. | Moderuje: Juraj Turis. | Talkshow Hosť Rádia Regina Západ pripravuje Slovenský rozhlas, Rádio Regina Západ, RRZ.

It's time for another Life in the Fast Lane and a discussion about The Arbor King... Groot... Doomsday. We kick off with Minute 30 from Tokyo Drift, featuring cutting-edge flip phone technology! (Can we buy those phones?) We then make a triumphant return to Run the VIN, with nine (!) posts! Vin is in (nearly) full-blown Fast Forever mode, but we also learn things like: he's a twin and his dad is from Oakland? In the news roundup, Vin's daughter joins him on the red carpet. We talk about cars we've owned, get some more alternate titles for Fast Forever, and hear about and a new way to air Dos Bandoleros. We talk (spoiler free) about Matt Johnson's filmography, Scream 7, The Pitt, and DTF St. Louis. Email us: ⁠⁠⁠⁠family@cageclub.me⁠⁠⁠⁠⁠⁠⁠⁠Visit our Patreon page at patreon.com/2fast2forever⁠⁠⁠⁠. ⁠⁠⁠⁠Show your support at the 2 Fast 2 Forever shop⁠⁠⁠⁠!Extra special shout-out to Alex Elonen, Brian Rodriguez (High School Slumber Party), Lane Middleton, Jason Rainey, Wes Hampton, Josh Buckley (Whole Lotta Wolves), Michael Moser, Terra New One, Aaron Woloszyn, and Randy Carter for joining at the “Interpol's Most Wanted” level or above!Intro music by Nico Vasilo. Interlude and outro music by Wes Hampton.

As a new adaptation of Emily Bronte's Yorkshire-set novel Wuthering Heights hits cinemas, Ellen E Jones and Mark Kermode look at how the area known as God's Own Country has been depicted in film and television.Mark speaks to Pulp frontman Jarvis Cocker about his love for the 1969 Ken Loach film Kes, and about why the city of Sheffield was the perfect setting for the post-apocalyptic TV drama Threads. And Mark also speaks to Clio Barnard - the writer-director behind such acclaimed films as The Arbor, The Selfish Giant and Ali & Ava - about why she is repeatedly drawn to Yorkshire in her film-making. Meanwhile, Ellen talks to Sally Wainwright, the prolific TV writer who has made her name with a series of insightful, essential television dramas set in Yorkshire, from At Home with the Braithwaites to Riot Women. Producer: Jane Long A Prospect Street production for BBC Radio 4

Michael and Jake catch up on what's been occupying their time lately, from AI tooling experiments to new developer workflows, before closing with a broader reflection on how new technologies are often misunderstood at first.Show linksOpenClaw / Clawd Bot / MoltbotArborAI horseless carriages

In this episode of The Golden Gang, host James sits down with Alba Gallo, a culinary chef who joined Arbor Terrace Shrewsbury in September 2024. Alba shares how her family's Florida food truck sparked her passion for cooking, what led her to earn a culinary degree, and why she's spent 15 years bringing comfort and creativity to senior living dining. Hear her take on why mealtimes matter so much to residents—and the Italian classics she loves making most.

In this episode, Ron Wilson, your personal yard boy, welcomes the Arbor Doctor, to share his winter weather prediction. Ron's forecast is based on his unique approach to meteorology, which considers the start of meteorological winter. He predicts six more weeks of winter-like weather, with some areas potentially experiencing even colder temperatures. Ron also discusses the importance of choosing the right plants for your hardiness zone and how snow can be a great insulator for plants. This episode is a must-listen for anyone curious about winter weather and gardening tips.See omnystudio.com/listener for privacy information.

WXPR News for 1-18-26

Here in the Garden with Ron Wilson, Ron's chatting with certified arborist Ron Rothhaas about trees. They're discussing common mistakes homeowners make when it comes to tree care, like planting too deep and topping trees. Ron shares his expertise on how to prune trees structurally, emphasizing the importance of considering the tree's future growth and not cutting off too many branches at once. They also talk about cabling and filling holes in trees, and how to handle winter issues like frost cracks and bronzing. It's a valuable conversation for anyone looking to learn more about tree care and maintenance.See omnystudio.com/listener for privacy information.

Ron Wilson's back in the garden, chatting with the Arbor Doc, They dive into the world of meteorology vs. astrology in weather forecasting, with Ron explaining the benefits of using meteorological seasons, which align with plant growth and temperature patterns. Scott's still learning, but Ron's expertise shines through. They also discuss tree care, with Ron sharing tips on pruning and root systems, and even touch on a potential side business idea – turning hollowed-out tree trunks into unique furniture pieces.See omnystudio.com/listener for privacy information.

Ron Wilson chats with the Arbor Doc as he shares his expertise as a certified arborist and amateur meteorologist. He discusses the upcoming winter season, predicting a roller coaster of temperatures with warm weather expected around Christmas, followed by a return to cold and snowy conditions in January and February. Ron also touches on the importance of watering evergreens, noting that the ground is currently wet due to recent precipitation, but areas in the northeast Ohio and northern Indiana are still experiencing drought. He emphasizes the need for careful watering in these regions.See omnystudio.com/listener for privacy information.

Pierre Turgeon, 2023 Hockey Hall of Fame inductee and one of only 48 players in NHL history to score 500 goals, joins Neil and Vic for an intimate Hall of Fame Edition conversation. From representing Canada in the Little League World Series alongside Stefan Matteau to scoring 132 points in his best NHL season, Turgeon reflects on his remarkable 19-year career. He shares memories of the Dale Hunter hit, the emotional closing of the Montreal Forum, playing alongside legends, and the personal tragedy that changed his perspective on life and gratitude.IN THIS EPISODE:[00:00] - Pierre Turgeon joins as the latest Hockey Hall of Fame Edition guest, one of 48 players with 500+ career goals.[01:00] - The quirky connection: playing for the Granby Bisons in junior hockey, then getting drafted by the Buffalo Bisons (Sabres).[02:00] - Early comfort in Buffalo: Jacques Cloutier as a fellow French-speaker helping ease the transition to the NHL.[03:00] - The incredible 1985-86 junior season: 114 points as a 16-year-old despite the team having four different head coaches.[04:00] - The meditation of hockey: being in the moment on the ice where nothing else matters - pure presence in the bubble.[05:00] - Little League World Series glory: representing Canada with Stefan Matteau, both 11-year-old pitchers alternating, finishing fourth.[06:00] - Playing at 5'11" as an 11-year-old, pitching in front of 25,000 fans, and the hero's welcome at the airport back home.[08:00] - Life in Colorado and Florida: visiting three kids and grandkids in Denver, spending time in Vail, embracing the Rockies and sports culture.[09:00] - The Dale Hunter hit in 1993 playoffs: scoring the series-clinching goal against Washington, the controversial blind-side hit, and Hunter's later apology.[10:00] - Al Arbor's leadership magic: making the Islanders believe they could beat Pittsburgh in 1993, winning Game 7 on David Volek's overtime goal.[11:00] - Dressing for Game 7 with one shoulder, ready to play overtime despite the injury, learning from Arbor's wisdom.[12:00] - Junior hockey connections: playing with Stefan Richer and Stephan Quintal, now skating together in Florida.[14:00] - The hilarious Stefan Richer story: "Can't tell" his name at a Boston diner leading to confused locals with heavy accents.[15:00] - Clark Gillies' impact: the intimidating beard in Buffalo, later becoming a great friend and storyteller on Long Island.[16:00] - Six years with Benoit Hogue: playing together in Buffalo, New York (Islanders), and Dallas - lifelong friendship.[17:00] - The Clint Malarchuk incident, March 22, 1989: witnessing hockey's worst accident, the army medic trainer's quick response saving a life.[19:00] - Hall of Fame journey: first eligible in 2010, inducted in 2023 - the platform to thank people who helped along the way.[22:00] - Playing only 104 games for the Canadiens but being honored with the most memorable moment of his career.[24:00] - March 11, 1996: The closing of the Montreal Forum, the seven-minute standing ovation for Maurice Richard, walking the red carpet.[25:00] - Being the final Canadiens captain to exit the Forum: receiving the torch from Butch Bouchard, Jean Beliveau, and the legends.[26:00] - Family sacrifice: time away from family, the support system, coaching kids' hockey after retiring.[27:00] - The unimaginable tragedy: losing daughter Jenna at 18 in a car accident in 2010, two years stuck in mud, learning to live with loss.[29:00] - Giving back all the highlights: the Hall of Fame, the goals, the captaincy - all of it for one more moment with her.[30:00] - Living in the moment: appreciating birds, branches, trees, mountains, water - finding beauty in small things and embracing gratitude.[31:00] - Golf as connection with nature: competitive but...

Today on "Hot Mic", Hutt and Chad discuss Michigan firing Sherrone Moore with cause and is Kalen DeBoer really a candidate in An Arbor? Plus, the Boys breakdown a hypothetical CFP secondary NIL tournament bracket. And GA Senate Candidate, Derek Dooley joins the show to share his thoughts on Notre Dames reaction to missing out on the CFP, why Georgia is the gold standard right now in college football and does Congress need to step in and fix the system in CFB? Learn more about your ad choices. Visit podcastchoices.com/adchoices

Hosted on Acast. See acast.com/privacy for more information.

# A Weather-Watching Arborist Shares Tree Wisdom and Winter Forecasts In this engaging episode, renowned arborist Ron Rothhaas brings his expertise to the garden, discussing everything from the fate of recovering ash trees to the best choices for street tree plantings. With his unique combination of tree knowledge and meteorological insight, Ron offers practical advice for homeowners while sharing his predictions for an unusually snowy December across the Midwest and Northeast. ## Episode Highlights: **3:15** - Emerald ash borer update: Ron explains that while the insect remains present in smaller numbers, treatment protocols have been extended from every two years to every three years, and some untreated ash trees show surprising resilience. **9:20** - Street tree selection: Discussion of infrastructure damage from tree roots, with recommendations for black gum and ginkgo over red maple in limited planting spaces. **12:05** - Winter pruning benefits: Why arborists prefer dormant-season pruning for oaks to prevent oak wilt disease, plus structural pruning tips for young trees. **18:40** - Winter weather outlook: Detailed forecast of an active storm pattern bringing significant snow to the Midwest, with Cincinnati potentially facing accumulating snow by Tuesday morning. **21:30** - White Christmas predictions: Ron breaks from his usual "50% chance" stance, suggesting significantly higher odds this year for the Ohio Valley and Northeast regions. Whether you're managing trees on your property or preparing for winter weather, Ron combines scientific knowledge with practical experience to help you make informed decisions. Listen now to benefit from his decades of expertise in both arboriculture and meteorology!See omnystudio.com/listener for privacy information.

Listen in on an exciting conversation Scott Cline has with Rick and Cindy Taylor, the Founders of Arbor Eyewear! The timing of this conversation couldn't be better since one of Arbor's foundational pillars is philanthropy and they give back to many organizations, including those who support adoption. November is National Adoption Month and Cindy and Rick share how adoption has touched their lives. Throughout the conversation, you will learn more about their philanthropic mindset, how each of their collections are special in their own way, and how they are bringing eyewear manufacturing back to the USA. To learn more about Arbor Eyewear and to connect with them, please reach out to us at info@acquiosalliance.com. You can also visit their website https://www.arboreyewear.com/. 

When Christine moved her mom, Mary, into Arbor Terrace Mount Laurel, she was looking for more than a beautiful building. She wanted people who would treat her mother like family.In this episode of The Golden Gang, host Phil Rizzo, Business Office Director at Arbor Terrace Mount Laurel, talks with Christine about her mom's three years in our community—and why Christine still stays involved even after Mary's passing at age 96.If you're exploring senior living in Burlington County, NJ, or simply want an inside look at what a meaningful connection can look like in a community, this episode is for you!

We want to hear from you! Send us a question or comment.The hardest truth for families to hear often becomes the most freeing: you can't fix your loved one's addiction—and you don't have to. We sat down with clinical leader Dr. Brian Samford and admissions director Zack Plyler from The Arbor, alongside interventionist Brian Schultz, to map out a path that replaces control with connection and panic with a plan. If you've been acting as the banker and the janitor—funding chaos and cleaning up every mess—this conversation shows how to step back into your real role: parent, partner, sibling.We unpack why codependency mirrors addiction, how enabling is really feelings‑avoidance, and why surrender is as essential for families as it is for those who use. You'll hear what healthy boundaries look like in practice, how to shift phone calls from progress‑policing to simple human connection, and why long‑term care matters more than a quick 30‑day stay. We also demystify the mental health vs. addiction debate, explaining how substance use disorder itself is a mental illness and why medicating symptoms without changing systems keeps everyone stuck.Looking for a real way to evaluate treatment? We share what to look for beyond glossy websites: staff presence versus office huddles, alumni working on campus, peers greeting newcomers by name, and support at 2 a.m. when it counts. Most of all, we return to the heart of lasting change: therapeutic alliance, community, and the kind of spiritual growth that shifts identity from shame to belonging. There is hope, and there is a path—Al‑Anon, ACA, CoDA for families; meetings, mentorship, and service for those seeking sobriety. Everyone has a part, and when each person does theirs, recovery becomes possible and sustainable.If this resonates, follow the show, share it with someone who needs it, and leave a review to help more families find practical hope. Your next right step might be closer than you think.Support the showJoin us Every Sunday at 8:00 PM PST and Monday, Tuesday, Wednesday and Thursday Night at 8:00 PM EST/5:00PST for a FREE family support group. Register at the following link to get the zoom information sent to you: Family Support MeetingAbout our sponsor(s):Intervention on Call is on online platform that allows families and support systems to get immediate coaching and direction from a professional interventionist. While a professional intervention can be a powerful experience for change, not every family needs a professionally led intervention. For families who either don't need or can't afford a professional intervention, we can help. Hour sessions are $150.Therapy is a very important way to take care of your mental health. This can happen from the comfort of your own home or office. If you need therapy and want to get a discount on your first month of services please try Better Help.If you want to know more about the host's private practice please visit:Matt Brown: Freedom InterventionsFollow the host on TikTokMatt: @mattbrowninterventionistIf you have a question that we can answer on the show, please email us at matt@partywreckers.com

In response to our episode on the Michigan Dogman, listener Linda Alice Dewey of Leelanau County wrote to us about her supernatural encounter that originated from a secluded, cemetery in Glen Arbor. The interaction resulted in a spirit driven book written by Dewey and co-authored by a ghost. Want to submit a question to On Hand? Do it here: Online Submission Form Call us: 734-764-7840 Email us: onhand@michiganpublic.org If you like what you hear on the pod, consider supporting our work: michiganpublic.org/podfundSee omnystudio.com/listener for privacy information.

Join the Two Tree Guys for an Innovation Talk with Andy Jones, co-founder of Rooted Arbor Care, as he shares his real-world journey leading a tree care company into the battery-powered era. Andy dives deep into testing top brands like Milwaukee, Husqvarna, Stihl, EGO, Makita, and Greenworks, revealing what worked, what didn't, and how his team optimized power management, charging setups, and crew efficiency in daily operations. Learn how Rooted Arbor Care achieved its best financial year yet while cutting fuel costs, improving sustainability, and proving that battery power can outperform gas in professional arbor work. From mobile charging systems to smart tool selection and scaling strategies, Andy's insights redefine what's possible for the modern tree care industry. ⚡

SCRIPTURE- 1 John 4:19"We love because he first loved us."REFLECTION- Fr. JasonMUSIC- "Through the Arbor" by Kevin Kern- "I Will Praise You, Lord, In the Assembly" (Psalm 22) by Paul Inwood- "Grace" by David TolkNOTES-PRAYER OF LETTING GOTo You do I belong, O God, into Your hands I surrender my life. Pour out Your Spirit upon me that I may love You perfectly, and serve You faithfully until my soul rests in You.

After three weeks of private contract negotiations between the University of California and UPTE representatives, workers at the UCSB campus are preparing to strike should a deal not be struck. Today, UPTE organizers gathered outside the Arbor at the UCSB campus to begin organizing efforts. What has led up to this moment, and how are workers feeling about the strike? Here's more from KCSB's Tatiana Jacquez.

The Arbor Doc talks about his trip and much more!

In episode #95 Victor Garcia joins us as we talk about Kai Kishi's Venture part, the Arbor Skateboards "Triad" video, the Deathwish "Introducing" video, Luan Oliveria off of Flip, The Nine Club Hotline and much more! Become a Channel Member & Receive Perks: https://www.youtube.com/TheNineClub/join New Merch: https://thenineclub.com Sponsored By: AG1: Get a FREE Welcome Kit worth $76 when you subscribe, including 5 AG1Travel Packs, a shaker, canister, scoop & bottle of AG Vitamin D3+K2. https://drinkag1.com/nineclub LMNT: Grab a free Sample Pack with 8 flavors when you buy any drink mix or Sparkling. https://drinklmnt.com/nineclub Woodward: Save $100 off summer camp with code NINECLUB. https://www.woodwardpa.com Bear Mattress: Delivered to your door with easy setup. Use code NINECLUB for 40% off your order. https://www.bearmattress.com Monster Energy: Monster Energy's got the punch you need to stay focused and fired up. https://www.monsterenergy.com Skullcandy: Feel the music with Skullcandy's custom-tuned audio—from the lyrics in your soul to the bass in your bones. https://www.skullcandy.com Yeti: Built for the wild, Yeti keeps you ready for any adventure. https://www.yeti.com éS Footwear: Get 20% off your purchase using our code NINECLUB or use our custom link. https://esskateboarding.com/NINECLUB Get 3 months of Full Self-Driving (Supervised) or $250 in Tesla Credits, or $400 off Solar Panel installation with my referral link: https://ts.la/chris39639 Find The Nine Club: Website: https://thenineclub.com Instagram: https://www.instagram.com/thenineclub X: https://www.twitter.com/thenineclub Facebook: https://www.facebook.com/thenineclub Discord: https://discord.gg/thenineclub Twitch: https://www.twitch.tv/nineclub Nine Club Clips: https://www.youtube.com/nineclubclips More Nine Club: https://www.youtube.com/morenineclub I'm Glad I'm Not Me: https://www.youtube.com/chrisroberts Chris Roberts: https://linktr.ee/Chrisroberts Learn more about your ad choices. Visit megaphone.fm/adchoices

Was hat die Künstliche Intelligenz (KI) zum Thema Essen und nachhaltige Ernährung zu sagen? Findet sie es ok, das Wissen und den Content dafür aus dem Web abzusaugen und glaubt sie daran, wirklich selbst einmal etwas schmecken zu können? Diese Fragen habe ich der Künstlichen Intelligenz in der aktuellen Podcast-Episode gestellt. Ein Experiment, das mich mit vielen Fragen zurücklässt, wie sehr die KI unser Leben in jeder Hinsicht noch beeinflussen wird. Es ist erschreckend und faszinierend zugleich, wie echt sie herüberkommt, fast wie ein realer Mensch. Am besten, du überzeugst dich selbst, wenn du dir diese Episode anhörst. Ich freue mich auf dein Feedback dazu. Ich habe übrigens eine männliche Stimme gewählt und die Künstliche Intelligenz auch gleich gefragt, wie mein „Gesprächspartner Arbor“ aussieht. Das Bild der KI habe ich ins Podcast-Cover eingebaut.

Send us a textAfter a long ass drive I am back home from the wedding weekend. The story begins there and ends up with me asking for help. Arbor is back with some random ideas and questionable answers. Take a ride with me on my soap box as I complain about all that I have while continually adding to the empire. I guess at the end of the day, the only one I can blame is myself. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Chiesi has entered a $2.1 billion collaboration with Arbor to develop a gene therapy for primary hyperoxaluria type 1. AstraZeneca continues to invest in AI partnerships, FDA lifts clinical hold on Neurizon's ALS drug, and the cell and gene therapy field faces challenges and opportunities at the Meeting on the Mesa event. CDC adopts ACIP recommendations, FDA's manufacturing initiatives progress, and Mythic cuts staff.Industry leaders in the cell and gene therapy space are gathering in Phoenix for a meeting on the mesa, where the market is experiencing mixed signals. While M&A activity and regulatory support are showing momentum, challenges with commercialization are still hindering investor interest. The focus on next-generation multiple sclerosis treatments beyond BTK inhibitors is gaining attention, with companies like Immunic Therapeutics exploring neuroprotective targets and remyelination.The future of gene therapy depends on improving safety through targeted delivery and human-relevant testing to avoid costly failures. The FDA has released new guidance to streamline regulatory pathways for cell and gene therapies for small populations, which is receiving a warmer welcome compared to previous issuances. In other news, the US government shut down, leading to the FDA closing for new applications, while Amgen presents late-stage data for Repatha in preventing heart disease.Additionally, Metsera's obesity drug shows promising efficacy in mid-stage trials. Cybersecurity is highlighted as a crucial challenge in the pharmaceutical industry, with a focus on protecting manufacturing integrity and innovation. Upcoming events include webinars on mRNA medicine and biopharma deregulation, while job opportunities in various biopharma companies are also available.Support the show

Host Phil, Business Office Director at Arbor Terrace Mount Laurel, sits down with community performer Cathy to explore her lifelong love of music. From growing up in Brooklyn and performing in bands to auditioning for Meat Loaf and leading a Pat Benatar tribute act, Cathy shares the journey that shaped her as an artist. She also reflects on why performing for seniors is the most rewarding part of her career—the smiles, the memories, and the joy music brings to residents and families alike.Interested in life at Arbor Terrace Mount Laurel? Call 856-367-3006 to schedule a tour,

In this episode I speak with John T Baker, The Arbor Studio, about owning and running a studio.  Sponsor: Feral Giant Theme song: Adeem The Artist

On this episode of The Golden Gang, Community Sales Director Amanda sits down with Resident Ambassador Claire of Arbor Terrace Morris Plains. Claire shares her remarkable path from raising five sons to a decades-long career in public service—recreation director, welfare director, and eventually director of human services—where she championed seniors with programs that brought thousands together. She also reflects on choosing assisted living after her husband passed, staying active with family and friends, and why Arbor Terrace fits her lifestyle today.

This week on The Golden Gang Podcast, join us in our beautiful The Arbor at Bridgemill community to meet Rose, a beloved resident whose zest for life has carried her through nearly a century of adventures. From triumphs in the world of sports to lifelong friendships and even a roller derby victory, Rose's story is full of laughter, courage, and inspiration to step outside of your comfort zone and live fully.

 30 Years in the Making and Oh Yes, Can I Borrow Your Belt?I first met Tim when he worked for (I think this is the name – it's so long ago it is outside of the ken of the World Wobly Web) Lex Software who had built, with Microsoft, an Executive Information System (EPM/CPM in today's language) toolkit that married Excel to what was then Arbor's Essbase (at least I think this is what it was). Tim was the teacher and we (my fellow J&J Executive Information Systems colleagues) were learning about the new client/server paradigm. For any J&Jers out there, this was at 410 George Street, right across the street from Corporate; I believe it is still a J&J office.That is exactly everything I remember about that training session, other than this: Tim forgot his belt, felt self-conscious, sized me up as being (probably) nice and generally the same size, and asked if he could borrow a belt. With me as recent(ish) college graduate, I had exactly one black belt to go with my suit (everyone wore suits), that left my one other belt which, alas, you cannot see because of Buzzsprout's limitations.  Think brown braided belt with a brass buckle.  Truly, an artefact of the 1990s.I think Tim felt he was underdressed for J&J – at the time (and maybe still is – it's been 29 years since I last set foot in a J&J office) a very conservative and buttoned down place.The Past is a Foreign Country, They Do Things Differently ThereWhat was it like, boys and girls, when all and sundry wore a suit to work? Kind of like this:( Wow, again, you can't see it.  Buzzsprout, either you need to add graphics or poor old Cameron needs to get a clue.  Maybe both.  Try this link back to EPM Conversations.)No, that is not me (you are over on the website, right?), but in fact Tony Randall (Who knew I hobnobbed with Hollywood royalty?  I didn't, of course. AI can be a wondrous thing; I have no idea who the woman is.) What is accurate is this is how people dressed. I cannot speak for the woman, but that is a fine example of a charcoal grey sack suit and a repp tie -- my Ivy Style exemplar. Work environments are so different now, it's almost inconceivable. Such is the passage of time and through time reputations are made – Tim's is stellar as is this second part of his interview.Join us, won't you?

Learn these 5 insights in climate & clean energy, startup investment, AI tips, and mindfulness leadership. Join 20,000 who get my newsletter: https://entrepreneursforimpact.substack.com

Patrick McKenzie (patio11) is joined again by Ricki Heicklen to discuss the evolution of her trading education business, Arbor, one year after their first conversation. They dive deep into the pedagogy of trading, exploring how simulated markets teach concepts like adverse selection, team dynamics, and risk management through hands-on experience. Ricki shares war stories from the bootcamp trenches—infinite loop bugs that mirror Knight Capital's disaster, WiFi outages that create unexpected trading opportunities, and that the most successful trading teams often focus on internal team communication even more than trade execution or technical acumen.See the full transcript: https://www.complexsystemspodcast.com/think-like-a-trader-ricki-heicklen/–[Patrick notes: Complex Systems now produces occasional video episodes.You can access them directly on YouTube: https://www.youtube.com/@patio11podcast. My kids inform me that I'm supposed to tell you to like and subscribe.]–Links:Trading Camp : https://trading.camp/Metagame: https://www.metagame.games/#tickets Story of Knight Capital: https://www.sec.gov/files/litigation/admin/2013/34-70694.pdf–Timestamps:(00:00) Intro(00:46) Ricki's journey from trading to teaching(01:25) The birth of Arbor and first bootcamps(03:32) Developing a trader's mindset(05:53) Understanding heuristics in trading(08:21) Adverse selection in everyday life(15:40) Insights from teaching trading bootcamps(21:07) Pedagogical approach: learning by doing(32:00) Handling mistakes and learning opportunities(36:17) Unplanned bugs and real-world lessons(39:47) Learning from Knight Capital's bug(40:24) Understanding exchange-side bugs(43:10) Risk limits and strategy separation(44:41) Importance of UI in trading bots(46:53) The Madagascar button(48:20) The big red button in manufacturing(49:45) Simulated trading and information aggregation(50:29) Sibling trading game explained(53:24) Modeling and hidden information(01:01:15) Trading behavior and market updates(01:04:38) Real-world applications and lessons(01:13:58) Surprises and market opportunities(01:16:24) Pedagogical approaches in trading education(01:17:08) Market dynamics and counterparty behavior(01:17:53) Retail vs. institutional order flow(01:19:23) Simplifying trading concepts for beginners(01:21:27) Introducing market characters and their roles(01:31:31) Team dynamics and communication in trading(01:39:13) The importance of redundancy in trading systems(01:47:52) Future of trading education and online classes(01:53:47) Wrap

Paul Jamison sits down with Joshua Marotta in downtown Atlanta to explore the inspiring journey of Atlanta Arbor Tree Care, covering team building, strategic pricing, and how CallRail enhances their marketing.